Taltz (ixekizumab) vs Wezlana (ustekinumab-auub)
Taltz (ixekizumab) vs Wezlana (ustekinumab-auub)
Taltz (ixekizumab) and Wezlana (ustekinumab-auub) are both biologic medications used to treat moderate to severe plaque psoriasis, among other conditions, but they target different proteins involved in the inflammatory process. Taltz blocks interleukin-17A (IL-17A), which is thought to play a key role in driving the inflammation associated with psoriasis, potentially leading to rapid skin clearance. In contrast, Wezlana, a biosimilar to Stelara (ustekinumab), blocks interleukins 12 and 23, offering a different mechanism of action that may be preferable depending on an individual's specific condition, medical history, and response to treatment.
Difference between Taltz and Wezlana
Metric | Taltz (ixekizumab) | Wezlana (ustekinumab-auub) |
---|---|---|
Generic name | Ixekizumab | Ustekinumab-auub |
Indications | Plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis | Plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis |
Mechanism of action | Interleukin-17A antagonist | Interleukin-12 and -23 antagonist |
Brand names | Taltz | Wezlana |
Administrative route | Subcutaneous injection | Subcutaneous injection |
Side effects | Injection site reactions, Upper respiratory infections, Nausea, Fungal infections | Infections, Injection site reactions, Headache, Fatigue |
Contraindications | Hypersensitivity to ixekizumab or any of the excipients | Hypersensitivity to ustekinumab or any of the excipients |
Drug class | Monoclonal antibody | Monoclonal antibody |
Manufacturer | Eli Lilly and Company | Janssen Biotech, Inc. |
Efficacy
Efficacy of Taltz (Ixekizumab) in Treating Psoriasis
Taltz (ixekizumab) is an immunosuppressant that is specifically designed to treat moderate to severe plaque psoriasis in adults who may benefit from systemic therapy or phototherapy. It is a biologic medication that works by targeting interleukin 17A (IL-17A), a protein that plays a significant role in the development of psoriatic plaques. Clinical trials have demonstrated that Taltz can lead to significant skin clearance. In these trials, many patients achieved a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) after just 12 weeks of treatment, and some even reached PASI 90 or PASI 100, indicating near-complete or complete clearance of skin lesions.
The efficacy of Taltz has been sustained in long-term studies, with a good proportion of patients maintaining significant skin clearance over a period of 60 weeks and beyond. The safety and efficacy of Taltz in the treatment of psoriatic arthritis have also been established, providing an additional benefit for psoriasis patients who may suffer from this related condition. However, it is important to note that individual responses to Taltz can vary, and some patients may experience a lesser degree of skin clearance.
Efficacy of Wezlana (Ustekinumab-auub) in Treating Psoriasis
Wezlana (ustekinumab-auub) is another biologic medication approved for the treatment of moderate to severe plaque psoriasis in adults. It is a biosimilar to the original ustekinumab, which means it is highly similar to an already FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety, purity, and potency. Ustekinumab targets interleukin 12 and interleukin 23, cytokines involved in inflammatory and immune responses, including the pathogenesis of psoriasis.
Clinical studies have shown that Wezlana is effective in achieving significant skin clearance in patients with plaque psoriasis. A majority of patients treated with ustekinumab can achieve PASI 75 within 12 weeks, and some patients may even attain PASI 90 or PASI 100, indicating an excellent response to treatment. The long-term efficacy of ustekinumab has been established, with many patients maintaining treatment response with continued therapy. As with other biologics, the response to Wezlana can vary among individuals.
Regulatory Agency Approvals
Taltz
Wezlana
Access Taltz or Wezlana today
If Taltz or Wezlana are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us